Alagille Syndrome

Odevixibat shows sustained efficacy and safety in long-term Phase 3 studies for PFIC and Alagille syndrome

Long-term data from two Phase 3 extension studies assessing odevixibat for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS) were presented at the American Association for the Study of Liver Diseases' 75th Liver Meeting. In the PEDFIC 2 study, odevixibat demonstrated sustained reductions in pruritus and serum bile acids...